

CIF A-18.758.300  
Avda de la Innovación, n 1  
Edificio BIC (Ofic 211)  
P. T. de Ciencias de la Salud  
18100 Armilla (Granada)  
**Tel: 958 750 598**

Mercado Alternativo Bursátil  
Plaza de la Lealtad, 1  
28014

Granada, a 29 de mayo de 2014

## **HECHO RELEVANTE NEURON BIOPHARMA, S.A.**

Muy Sres. Nuestros:

En cumplimiento con lo dispuesto en la Circular 9/2010 del MAB sobre información a suministrar por empresas en expansión incorporadas a negociación en el MAB, por la presente se pone en conocimiento la siguiente información relativa a Neuron Biopharma, S.A.

La Compañía ha participado en el 10º Foro Medcap de empresas de mediana capitalización, organizado por Bolsas y Mercados Españoles. Adjuntamos la presentación corporativa que se ha utilizado en dicho foro.

Atentamente,

D. Fernando Valdivieso Amate  
Presidente del Consejo de Administración



**Madrid**  
**28 mayo 2014**



NEURON  
BIO



# The company

## Significant milestones






# Structure: 2006-2013



# Mission & Vision



## Mission

Creation, development and management of biotechnological companies

## Vision

To be recognized as an international reference in the medical biotechnology during the next five years



# Overview

**COMPANY PROFILE:** Quoted on the **Spanish Alternative Stock Market (MAB)**

## **LOCATIONS:**

- Granada Health-Science Technology Park (headquarters)
- Madrid Science Park (laboratory, animal facilities & offices)

## **BUSINESS LINES:**


- Drug Discovery&Development
- Development of diagnostics tools
- R&D bioservices

## **MANAGEMENT:**

- **UNE166.002** (Standard Operating Procedure for R&D)
- **SGE21** (Ethical and CSR Management System)

## **R&D:**

- **More than 50 years of accumulated postdoctoral experience** in R&D
- Participation in 15 scientific projects
- Property of a wide **collection of molecules** (new chemical entities and reprofiling drugs) and natural products (>20.000 plant and microbial extracts)
- Over **€10 million so far invested** in R&D



# Strengths



**TEAM:** 23 people on the staff, 10 of them doctors, a Board of Directors with wide business experience and an internationally recognized scientific advisory board

**TECHNOLOGY:** Exclusive **Drug Discovery & Development Platform** consisting in:

- A Screening Platform to identify potential neuroprotective candidates (high-throughput technologies)
- A Preclinical Platform to select the better in vivo candidate and perform its development and optimization
- More than 50 different technologies including in silico, in vitro and cellular assays as well as animal models
- Efficacy, safety and pharmacokinetics

## **MARKETS:**


**Global Central Nervous System (CNS) market: \$71 billion in 2010**

- Neurodegenerative disorders market: >\$21 billion in 2009
- Alzheimer's disease (AD): \$8 billion in 2009 and \$9.6 billion in 2014 (expected)
- Drugs against AD: >\$4.2 billion in 2012
- Diagnostic tools against AD: \$1.2 billion in 2009 and \$2.9 billion in 2014 (expected)

**Global R&D services market: \$85-105 billion in 2013**

- Non-clinical research market: \$11-15 billion in 2013

# Holding structure: 2014







- 1. COMPANY PROFILE**
- 2. MISSION**
- 3. OPPORTUNITY DESCRIPTION**
- 4. SOLUTION PROPOSAL**
- 5. KEY DIFFERENTIAL STRATEGY**
- 6. BUSINESS RISK  
DIVERSIFICATION & CONTINGENCY  
STRATEGIES:**
- 7. BUSSINESS MODEL**
- 8. NEXT STEPS**





**1. COMPANY PROFILE:** Public company quoting on the **Spanish Alternative Stock Market (MAB)**

**2. MISSION:** Creation, development and management of **biotech companies**

**3. OPPORTUNITY DESCRIPTION:**

- The global biotechnology market in 2016 is forecast to have a value of **>\$450 billion\***
- Medical/healthcare is **the largest segment** of the global biotechnology market (67%)\*
- Americas accounts for 45% of the global biotechnology market value\*

**4. SOLUTION PROPOSAL:**

- Neuron Bio has been specialized in the last years in the biotech market, generating and developing new companies with an increasing value



## 5. KEY DIFFERENTIAL STRATEGY :

- **Hybrid strategy** (services for clients and generation of value for stakeholders)
- Holding structure with **several companies in the group**

## 6. BUSINESS RISK DIVERSIFICATION & CONTINGENCY STRATEGIES:

- **Diversity** in the business lines
- Capacity to generate **new business**

## 7. BUSSINESS MODEL:

- **Sale of participations** of the subsidiary companies
- **Exploitation** of the Neuron Bio facilities and laboratories
- **Sale of services** for clients
- **Co-developments** with strategic partners

## 8. NEXT STEPS:

- 1) To move to the **new headquarters** (6 months)
- 2) To reach the **funding** for the subsidiary companies (12 months)
- 3) To increase the **visibility** of the group (12 months)

- 1. PROFILE**
- 2. MISSION**
- 3. OPPORTUNITY DESCRIPTION**
- 4. SOLUTION PROPOSAL**
- 5. BUSINESS MODEL**




- 1. PROFILE:** Neuron Bio trademark to commercialize R&D bioservices
- 2. MISSION:** To offer **integrated preclinical solutions** for pharmaceutical, biotechnology and agro-food companies
- 3. OPPORTUNITY DESCRIPTION:**
  - The global market for drug discovery & development is over **\$85 billion**
  - The **main therapeutic markets** are autoimmune diseases, Central Nervous System, cardiovascular, infection, obesity and oncology
  - In 2010, the US nutraceutical market stood at **\$50.4 billion** and was by far the largest nutraceutical market in the world






## 4. SOLUTION PROPOSAL:

- An exclusive **Screening & Preclinical Platform** to study efficacy, safety and pharmacokinetics of molecules, extracts, ingredients, and natural products
- More than **50 different technologies** including *in silico*, *in vitro*, cellular assays and animal models (zebrafish and rodents)



- 5. BUSSINESS MODEL:** Offer solutions to agrofood, biotech and pharma companies in two different business lines:
- **R&D Services:** efficacy, safety, pharmacokinetics&pharmacodynamics, generation of experimental models, etc.
  - **Consulting:** management, laboratory design, training, communication, industrial property, fundraising, etc.





- 1. COMPANY PROFILE**
- 2. MISSION**
- 3. OPPORTUNITY DESCRIPTION**
- 4. SOLUTION PROPOSAL**
- 5. KEY DIFFERENTIAL STRATEGY**
- 6. BUSINESS RISK DIVERSIFICATION & CONTINGENCY STRATEGIES:**
- 7. BUSSINESS MODEL**
- 8. NEXT STEPS**





**1. COMPANY PROFILE:** Private company

**2. MISSION:** Discovery and development of compounds for prevention or treatment of neurodegenerative and **central nervous system diseases**

**3. OPPORTUNITY DESCRIPTION:**

- More than **44 million people** suffer from neurodegenerative disorders
- The global economic cost for Alzheimer's disease (AD) is **\$640 billion**
- The drug market for AD exceeded **\$4.2 billion** in 2012
- There are **not effective treatments** against AD






#### 4. SOLUTION PROPOSAL:

- Research focused on **central nervous system diseases**, mainly AD
- Aiming at **innovative targets** different from classical ones ( $\beta$ -amyloid)
- Development of **neuroprotectants**
- A **Pipeline** with 5 novel and patented neuroprotective compounds against early stages of Alzheimer's disease, and belonging to three groups of molecules:

PRODUCT	TYPE OF MOLECULE	THERAPEUTIC AREA	INDICATION	SCREENING	EFFICACY	REGULATORY	PHASE I
<b>NST0037</b>	Statin derivatives	CNS	MCI	■■■	■■■	■■■	■
<b>NST0060</b>				■■■	■■■	■■■	■
<b>NST0076</b>	3rd-generation neuroprotective molecules	CNS	MCI	■■■	■■■	■	NST Projects
<b>NST0078</b>				■■■	■■■	■	
<b>NPS0163</b>	Xantocillin derivative	CNS	MCI	■■■	■■■	■	NPS, SCR and XAN Projects



## 5. KEY DIFFERENTIAL STRATEGY TO ADDRESS ALZHEIMER'S DISEASE:

- Development of molecules with **more than one mechanism-of-action**
- Search for **disease-modifier** therapies focused on the **early stages** of the disease
- **Translational research** to reduce attrition in clinical trials
- Identification of **novel mechanisms of neuroprotection** to design new therapeutic strategies

## 6. BUSINESS RISK DIVERSIFICATION & CONTINGENCY STRATEGIES:

- **Diversity** in the drug pipeline
- Availability of **back-up molecules** in each pharmacological group
- Development of neuroprotective compounds aimed at **different neurological disorders**, not only AD
- Molecules with **additional properties** to neuroprotection
- Feasible identification of **new candidates** and easily and fast preclinical development




## **7. BUSSINESS MODEL:**

- Sale of exploitation licenses for the **neuroprotective compounds**
- Sale of use and exploitation licenses for the **Drug Discovery & Development platform** and compound evaluation

## **8. NEXT STEPS:**

- 1) **NST0037** phase I (12 months)
- 2) Regulatory preclinical studies of **NST0076** or **NST0078** (18 months)
- 3) Preclinical efficacy studies of **NPS0163** (16 months)







## **1. COMPANY PROFILE**

## **2. MISSION**


## **3. OPPORTUNITY DESCRIPTION**

## **4. SOLUTION PROPOSAL**

## **5. KEY DIFFERENTIAL STRATEGY**

## **6. BUSINESS RISK DIVERSIFICATION & CONTINGENCY STRATEGIES**

## **7. BUSSINESS MODEL**





# BIO NEURON

**1. COMPANY PROFILE:** Private company

**2. MISSION:** Development of **diagnostic and prognostic tools** for human diseases with especial focus to neurological/neurodegenerative disorders

**3. OPPORTUNITY DESCRIPTION:**

- There are a **unmet diagnostic needs** for several human diseases, especially in the nervous disorders such as the Alzheimer's disease (AD)
- Diagnostic/biomarkers is the **2<sup>nd</sup>-largest segment** of the AD-market (\$2.9 billion in 2014)

**4. SOLUTION PROPOSAL:**

- Develop a **novel diagnostic tool** from early stages of AD
- Diagnostic tool that will identify **individuals with high risk** to develop AD



## 5. KEY DIFFERENTIAL STRATEGY TO ADDRESS ALZHEIMER'S DISEASE:

- Focused in the **discrimination** of individuals with MCI, AD, or healthy
- **Minimally invasive** sample collection
- **Combination** of biological fluids (saliva, blood...)
- Biomarker-based tool on **various mechanisms-of-action**

## 6. BUSINESS RISK DIVERSIFICATION & CONTINGENCY STRATEGIES:

- Additional approaches to **expand the range of biomarkers** to analyze
- Identification of biomarker **for other dementias**
- To offer **diagnostics services** using our biomarker analysis platform and medical network

## 7. BUSSINESS MODEL: Sale of exploitation licenses for the discriminatory tool for:

- **Big Pharma Companies**
- **Diagnostics Companies**





Avda. Innovación nº1  
Granada 181016 (Spain)  
Tel. [+34] 958 750 598  
[iburgos@neuronbio.com](mailto:iburgos@neuronbio.com)



[www.neuronbio.com](http://www.neuronbio.com)  
[www.neuronbiopharma.com](http://www.neuronbiopharma.com)  
[www.neuronbioservices.com](http://www.neuronbioservices.com)

